Amgen Tax Provision vs Net Income From Continuing Ops Analysis

AMGN Stock

USD 312.47 2.25 0.71%

Amgen financial indicator trend analysis is way more than just evaluating Amgen Inc prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Amgen Inc is a good investment. Please check the relationship between Amgen Tax Provision and its Net Income From Continuing Ops accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amgen Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.

Tax Provision vs Net Income From Continuing Ops

Tax Provision vs Net Income From Continuing Ops Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Amgen Inc Tax Provision account and Net Income From Continuing Ops. At this time, the significance of the direction appears to have strong contrarian relationship.

The correlation between Amgen's Tax Provision and Net Income From Continuing Ops is -0.58. Overlapping area represents the amount of variation of Tax Provision that can explain the historical movement of Net Income From Continuing Ops in the same time period over historical financial statements of Amgen Inc, assuming nothing else is changed. The correlation between historical values of Amgen's Tax Provision and Net Income From Continuing Ops is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Tax Provision of Amgen Inc are associated (or correlated) with its Net Income From Continuing Ops. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Income From Continuing Ops has no effect on the direction of Tax Provision i.e., Amgen's Tax Provision and Net Income From Continuing Ops go up and down completely randomly.

Correlation Coefficient

-0.58

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Tax Provision

The amount set aside by a company to cover any estimated taxes for the current period. It reflects the company's expected tax liabilities.

Net Income From Continuing Ops

Most indicators from Amgen's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Amgen Inc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amgen Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.

At this time, Amgen's Selling General Administrative is very stable compared to the past year. As of the 17th of May 2024, Tax Provision is likely to grow to about 1.4 B, while Enterprise Value Over EBITDA is likely to drop 11.29.

	2021	2022	2023	2024 (projected)
Interest Expense	1.2B	1.4B	2.9B	3.0B
Depreciation And Amortization	3.4B	3.4B	4.1B	4.3B

Interest Expense Depreciation And Amortization

Amgen fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Inventory	Accounts Payable	Common Stock Total Equity	Short Term Investments	Capital Stock
Total Assets		0.93	0.74	0.81	0.33	0.65	0.94	-0.4	0.67	0.86	0.63	0.35	0.78	-0.49	0.92	-0.19	0.47	0.91	0.63	0.52	0.26	0.76	0.81	0.79	0.37	0.77
Short Long Term Debt Total	0.93		0.89	0.91	-0.01	0.47	0.99	-0.61	0.83	0.95	0.84	0.02	0.94	-0.55	0.99	-0.25	0.72	0.99	0.81	0.21	0.12	0.95	0.82	0.64	0.08	0.6
Other Current Liab	0.74	0.89		0.95	-0.37	0.39	0.85	-0.88	0.93	0.92	0.95	-0.3	0.99	-0.73	0.92	-0.21	0.84	0.94	0.9	-0.07	-0.06	0.93	0.88	0.58	-0.29	0.54
Total Current Liabilities	0.81	0.91	0.95		-0.23	0.47	0.88	-0.81	0.87	0.9	0.83	-0.12	0.94	-0.76	0.92	-0.29	0.73	0.95	0.82	0.1	0.25	0.88	0.89	0.67	-0.12	0.63
Total Stockholder Equity	0.33	-0.01	-0.37	-0.23		0.39	0.07	0.66	-0.35	-0.12	-0.44	0.88	-0.29	0.37	-0.05	0.17	-0.51	-0.09	-0.36	0.79	0.36	-0.27	-0.11	0.31	0.88	0.36
Property Plant And Equipment Net	0.65	0.47	0.39	0.47	0.39		0.46	-0.32	0.42	0.47	0.21	0.4	0.4	-0.53	0.48	0.22	0.1	0.49	0.35	0.63	0.28	0.3	0.59	0.96	0.27	0.95
Net Debt	0.94	0.99	0.85	0.88	0.07	0.46		-0.53	0.76	0.93	0.79	0.09	0.89	-0.51	0.98	-0.32	0.68	0.97	0.76	0.27	0.17	0.92	0.8	0.63	0.16	0.59
Retained Earnings	-0.4	-0.61	-0.88	-0.81	0.66	-0.32	-0.53		-0.85	-0.71	-0.81	0.56	-0.82	0.79	-0.66	0.13	-0.74	-0.7	-0.79	0.33	0.11	-0.72	-0.76	-0.46	0.62	-0.43
Cash	0.67	0.83	0.93	0.87	-0.35	0.42	0.76	-0.85		0.85	0.88	-0.31	0.94	-0.58	0.85	0.08	0.79	0.87	0.87	-0.1	-0.1	0.89	0.77	0.56	-0.32	0.51
Non Current Assets Total	0.86	0.95	0.92	0.9	-0.12	0.47	0.93	-0.71	0.85		0.88	-0.18	0.95	-0.65	0.96	-0.26	0.74	0.96	0.83	0.04	0.01	0.94	0.85	0.65	-0.14	0.61
Non Currrent Assets Other	0.63	0.84	0.95	0.83	-0.44	0.21	0.79	-0.81	0.88	0.88		-0.44	0.95	-0.61	0.86	-0.22	0.9	0.86	0.91	-0.24	-0.28	0.93	0.74	0.39	-0.39	0.34
Cash And Short Term Investments	0.35	0.02	-0.3	-0.12	0.88	0.4	0.09	0.56	-0.31	-0.18	-0.44		-0.26	0.21	0.0	0.09	-0.48	-0.03	-0.34	0.94	0.49	-0.28	-0.01	0.35	0.97	0.39
Net Receivables	0.78	0.94	0.99	0.94	-0.29	0.4	0.89	-0.82	0.94	0.95	0.95	-0.26		-0.65	0.95	-0.17	0.84	0.96	0.91	-0.04	-0.04	0.97	0.84	0.58	-0.23	0.53
Common Stock Shares Outstanding	-0.49	-0.55	-0.73	-0.76	0.37	-0.53	-0.51	0.79	-0.58	-0.65	-0.61	0.21	-0.65		-0.61	0.39	-0.5	-0.65	-0.6	-0.07	-0.14	-0.51	-0.81	-0.68	0.31	-0.65
Non Current Liabilities Total	0.92	0.99	0.92	0.92	-0.05	0.48	0.98	-0.66	0.85	0.96	0.86	0.0	0.95	-0.61		-0.26	0.72	1.0	0.81	0.2	0.07	0.93	0.88	0.67	0.04	0.62
Other Current Assets	-0.19	-0.25	-0.21	-0.29	0.17	0.22	-0.32	0.13	0.08	-0.26	-0.22	0.09	-0.17	0.39	-0.26		-0.2	-0.27	-0.13	0.06	-0.26	-0.2	-0.28	0.03	-0.01	0.05
Other Stockholder Equity	0.47	0.72	0.84	0.73	-0.51	0.1	0.68	-0.74	0.79	0.74	0.9	-0.48	0.84	-0.5	0.72	-0.2		0.73	0.96	-0.31	-0.25	0.84	0.59	0.24	-0.42	0.18
Total Liab	0.91	0.99	0.94	0.95	-0.09	0.49	0.97	-0.7	0.87	0.96	0.86	-0.03	0.96	-0.65	1.0	-0.27	0.73		0.83	0.18	0.11	0.93	0.89	0.68	0.01	0.63
Property Plant And Equipment Gross	0.63	0.81	0.9	0.82	-0.36	0.35	0.76	-0.79	0.87	0.83	0.91	-0.34	0.91	-0.6	0.81	-0.13	0.96	0.83		-0.13	-0.16	0.87	0.73	0.47	-0.32	0.43
Total Current Assets	0.52	0.21	-0.07	0.1	0.79	0.63	0.27	0.33	-0.1	0.04	-0.24	0.94	-0.04	-0.07	0.2	0.06	-0.31	0.18	-0.13		0.5	-0.09	0.22	0.6	0.89	0.61
Short Term Debt	0.26	0.12	-0.06	0.25	0.36	0.28	0.17	0.11	-0.1	0.01	-0.28	0.49	-0.04	-0.14	0.07	-0.26	-0.25	0.11	-0.16	0.5		-0.07	0.05	0.31	0.47	0.32
Inventory	0.76	0.95	0.93	0.88	-0.27	0.3	0.92	-0.72	0.89	0.94	0.93	-0.28	0.97	-0.51	0.93	-0.2	0.84	0.93	0.87	-0.09	-0.07		0.74	0.47	-0.19	0.4
Accounts Payable	0.81	0.82	0.88	0.89	-0.11	0.59	0.8	-0.76	0.77	0.85	0.74	-0.01	0.84	-0.81	0.88	-0.28	0.59	0.89	0.73	0.22	0.05	0.74		0.77	-0.05	0.76
Common Stock Total Equity	0.79	0.64	0.58	0.67	0.31	0.96	0.63	-0.46	0.56	0.65	0.39	0.35	0.58	-0.68	0.67	0.03	0.24	0.68	0.47	0.6	0.31	0.47	0.77		0.24	0.99
Short Term Investments	0.37	0.08	-0.29	-0.12	0.88	0.27	0.16	0.62	-0.32	-0.14	-0.39	0.97	-0.23	0.31	0.04	-0.01	-0.42	0.01	-0.32	0.89	0.47	-0.19	-0.05	0.24		0.26
Capital Stock	0.77	0.6	0.54	0.63	0.36	0.95	0.59	-0.43	0.51	0.61	0.34	0.39	0.53	-0.65	0.62	0.05	0.18	0.63	0.43	0.61	0.32	0.4	0.76	0.99	0.26

Click cells to compare fundamentals

Amgen Account Relationship Matchups

Amgen fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	59.7B	62.9B	61.2B	65.1B	97.2B	102.0B
Short Long Term Debt Total	29.9B	33.0B	33.3B	38.9B	64.6B	67.8B
Other Current Liab	8.5B	10.1B	10.7B	12.5B	15.4B	16.1B
Total Current Liabilities	12.8B	11.7B	12.2B	15.7B	18.4B	19.3B
Total Stockholder Equity	9.7B	9.4B	6.7B	3.7B	6.2B	12.3B
Property Plant And Equipment Net	4.9B	4.9B	5.2B	5.4B	5.9B	3.6B
Net Debt	23.9B	26.7B	25.3B	31.3B	53.7B	56.4B
Retained Earnings	(21.3B)	(21.4B)	(24.6B)	(28.6B)	(26.5B)	(25.2B)
Cash	6.0B	6.3B	8.0B	7.6B	10.9B	11.5B
Non Current Assets Total	41.3B	41.8B	41.8B	42.9B	66.8B	70.2B
Non Currrent Assets Other	2.2B	5.6B	6.5B	5.9B	9.6B	10.1B
Cash And Short Term Investments	8.9B	10.6B	8.0B	9.3B	10.9B	10.5B
Net Receivables	4.1B	4.5B	4.9B	5.6B	7.9B	8.3B
Common Stock Shares Outstanding	609M	590M	573M	541M	538M	759.2M
Liabilities And Stockholders Equity	59.7B	62.9B	61.2B	65.1B	97.2B	102.0B
Non Current Liabilities Total	37.2B	41.9B	42.3B	45.8B	72.5B	76.2B
Other Current Assets	1.9B	2.1B	2.4B	2.4B	281M	267.0M
Other Stockholder Equity	(528M)	(985M)	18.2B	21.7B	25.0B	26.2B
Total Liab	50.0B	53.5B	54.5B	61.5B	90.9B	95.5B
Property Plant And Equipment Gross	4.9B	4.9B	14.0B	14.7B	15.7B	16.5B
Total Current Assets	18.4B	21.1B	19.4B	22.2B	30.3B	15.2B
Accumulated Other Comprehensive Income	(528M)	(985M)	(796M)	(231M)	(289M)	(274.6M)
Short Term Debt	3.0B	91M	87M	1.6B	1.4B	1.0B
Inventory	3.6B	3.9B	4.1B	4.9B	9.5B	10.0B
Accounts Payable	1.4B	1.4B	1.4B	1.6B	1.6B	1.7B
Common Stock Total Equity	31.5B	31.8B	32.1B	32.5B	37.4B	27.1B
Short Term Investments	2.9B	4.4B	48M	1.7B	10.9B	12.2B
Capital Stock	31.5B	31.8B	32.1B	32.5B	33.1B	27.5B
Common Stock	31.5B	31.8B	32.1B	32.5B	33.1B	27.5B
Other Assets	955M	1.3B	6.5B	2.2B	2.5B	1.4B
Long Term Debt	27.0B	32.9B	33.2B	37.4B	63.2B	66.3B
Property Plant Equipment	4.9B	4.9B	5.2B	5.4B	6.2B	5.3B
Good Will	14.7B	14.7B	14.9B	15.5B	18.6B	14.4B
Intangible Assets	19.4B	16.6B	15.2B	16.1B	32.6B	34.3B
Other Liab	9.9B	9.0B	9.1B	7.9B	9.1B	5.1B
Net Tangible Assets	(24.4B)	(21.9B)	(23.4B)	(27.9B)	(25.2B)	(23.9B)
Retained Earnings Total Equity	(21.3B)	(21.4B)	(24.6B)	(28.6B)	(25.8B)	(24.5B)
Long Term Debt Total	27.0B	32.9B	33.2B	37.4B	43.0B	29.9B
Non Current Liabilities Other	9.6B	9.0B	2.5B	2.7B	2.3B	2.2B

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Amgen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Amgen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Amgen Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Amgen Inc Stock:

How To Invest In Amgen

Details

Is Amgen Stock a good investment?

Details

What is Amgen's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amgen Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.

Note that the Amgen Inc information on this page should be used as a complementary analysis to other Amgen's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.

Complementary Tools for Amgen Stock analysis

When running Amgen's price analysis, check to measure Amgen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amgen is operating at the current time. Most of Amgen's value examination focuses on studying past and present price action to predict the probability of Amgen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amgen's price. Additionally, you may evaluate how the addition of Amgen to your portfolios can decrease your overall portfolio volatility.

	Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
	Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk
	Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios.
	Money Managers Screen money managers from public funds and ETFs managed around the world
	Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
	AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities
	Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios
	Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments
	Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators

Is Amgen's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amgen. If investors know Amgen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amgen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.52)

Dividend Share

8.64

Earnings Share

6.99

Revenue Per Share

55.148

Quarterly Revenue Growth

0.22

The market value of Amgen Inc is measured differently than its book value, which is the value of Amgen that is recorded on the company's balance sheet. Investors also form their own opinion of Amgen's value that differs from its market value or its book value, called intrinsic value, which is Amgen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amgen's market value can be influenced by many factors that don't directly affect Amgen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Amgen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Amgen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amgen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Amgen Tax Provision vs Net Income From Continuing Ops Analysis

Tax Provision vs Net Income From Continuing Ops

Tax Provision vs Net Income From Continuing Ops Correlation Analysis

Correlation Coefficient

Tax Provision

Net Income From Continuing Ops

Amgen fundamental ratios Correlations

Amgen Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Amgen fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Amgen Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Liab	+ 1.0	Non Current Liabilities Total
Net Debt	+ 0.99	Short Long Term Debt Total
Non Current Liabilities Total	+ 0.99	Short Long Term Debt Total
Total Liab	+ 0.99	Short Long Term Debt Total
Net Receivables	+ 0.99	Other Current Liab
Capital Stock	+ 0.99	Common Stock Total Equity

Retained Earnings	- 0.88	Other Current Liab
Cash	- 0.85	Retained Earnings
Net Receivables	- 0.82	Retained Earnings
Accounts Payable	- 0.81	Common Stock Shares Outstanding
Non Currrent Assets Other	- 0.81	Retained Earnings
Retained Earnings	- 0.81	Total Current Liabilities